Liposome News and Research

Latest Liposome News and Research

Nanocort demonstrates safety and good response in phase I/II trial for rheumatoid arthritis

Galapagos NV has announced that Nanocort has demonstrated safety as well as a faster and more pronounced decrease in rheumatoid arthritis disease symptoms compared to reference medication.

27 Oct 2008

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.

27 Oct 2008

Clinical trial advances cystic fibrosis therapy

Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.

4 Sep 2008

Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis

The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.

26 Jun 2008

Nanoparticles trigger built-in cell-death signal to overcome drug resistance

One of the most vexing problems in treating cancer is the propensity of tumors to develop resistance to a wide range of anticancer drugs. Over 70 percent of ovarian cancer patients, for example, have drug-resistant tumors at the time of their initial diagnosis, and virtually all patients who relapse have drug-resistant tumors.

15 Jun 2008

Nanoparticle delivers antisense agent to tumors

A multifunctional drug delivery system consisting of a lipid-based nanoparticle, a standard anticancer drug, and a short nucleic acid designed to augment the activity of that drug has demonstrated the ability to treat drug-resistant tumor cells.

15 Jun 2008

Human tumor nanoparticles induce apoptosis of pancreatic cancer cells

Using nanoparticles made from pieces of tumor cells, investigators from Aix-Marseille University in Marseille, France, have developed a new type of anticancer agent that appears to stop tumor cell growth and proliferation.

15 Jun 2008

Anticancer siRNA therapy advances, thanks to nanoparticles

Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.

28 Mar 2008

Next-generation nanomedicine

In an article featured on the cover of the March issue of Nature Nanotechnology, Mauro Ferrari, Ph.D., of The University of Texas Health Science Center at Houston, presented a proof-of-concept study on a new multistage delivery system (MDS) for imaging and therapeutic applications. This discovery could go a long way toward making injectable drugs more effective.

27 Mar 2008

Nanotechnology advances brain cancer detection and therapy

Brain cancer is one of the most aggressive and lethal of malignancies, made even more difficult to treat by the fact that most anticancer drugs have a hard time even getting to the tumors.

3 Mar 2008

Protein that stimulates blood vessel growth worsens ovarian cancer

A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Journal of the National Cancer Institute.

27 Feb 2008

New method to transfer DNA into a host cell

Genetically engineered products have become indispensable. For example, genetically modified bacteria produce human insulin.

21 Jan 2008

Matrix metalloproteinase-assisted triggered release of liposomal contents

Cancer cells display a variety of proteins on their outer membranes that are not present on the surface of normal cells.

16 Jan 2008

Viroporins, membrane-permeabilizing proteins of the poliomyelitis virus

A research team from the Universidad Autonoma de Madrid directed by Professor Luís Carrasco has published new discoveries concerning the membrane permeabilizing proteins of the polio virus.

16 Jan 2008

Intravenous gene therapy protects normal tissue of mice during whole-body radiation

Gene therapy administered intravenously could be an effective agent to protect vital organs and tissues from the effects of ionizing radiation in the event of large-scale exposure from a radiological or nuclear bomb, according to an animal study presented today by University of Pittsburgh researchers at the 49th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Los Angeles.

28 Oct 2007

Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery

In the quest to turn carbon nanotubes from nanoscale wonder into clinically useful drug and imaging agent delivery agents, researchers have often added polymer coatings to the outside of the nanotubes in order to render them biocompatible.

27 Sep 2007

Discovery of key HIV protein which makes cell membranes bend more easily

Carnegie Mellon University scientists have made an important discovery that aids the understanding of why HIV enters immune cells with ease.

26 Jul 2007

Gene therapy offers promising approach to tackle pancreatic cancer

A molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumors, inhibits metastasis, and prolongs survival with virtually no toxicity, researchers from The University of Texas M. D. Anderson Cancer Center report in the July 9 edition of Cancer Cell.

10 Jul 2007

Novel method of drug delivery to inhibit the growth of prostate cancer cells

Prostate cancer is the second leading cause of cancer-related death for men in the U.S. Present treatments for metastatic prostate cancer (cancer cells that spread to other parts of the body) include hormonal therapy, chemotherapy and radiotherapy, which frequently have serious side effects.

23 Jun 2007

Real-time, direct MRI monitoring of vector distribution within the brain

A team of scientists, led by Dr. Krystof Bankiewicz, University of California-San Francisco, presented this significant advance, which allows, for the first time, to adjust parameters of vector infusion while delivering gene therapy, giving surgeon full control over gene transfer technology.

3 Jun 2007